Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks

Yin-Ying Wang; Zhiguang Li; Tao Chen; Xing-Ming Zhao

Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks

View Fulltext

Author(s): Yin-Ying Wang ^{1, 2}^{1, 2} ; Zhiguang Li ³³ ; Tao Chen ⁴⁴ ; Xing-Ming Zhao ⁵⁵
- Affiliations: 1: Institute of Systems Biology, Shanghai University, Shanghai 200444, People's Republic of China;
  2: School of Communication and Information Engineering, Shanghai University, Shanghai 200444, People's Republic of China;
  3: Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, 9 Lvshun Road South, Dalian, Liaoning 116044, People's Republic of China;
  4: Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA;
  5: Department of Computer Science, School of Electronics and Information Engineering, Tongji University, Shanghai 201804, People's Republic of China
Source: Volume 9, Issue 4, August 2015, p. 141 – 146
DOI: 10.1049/iet-syb.2014.0057 , Print ISSN 1751-8849, Online ISSN 1751-8857

Received 17/12/2014, Accepted 14/02/2015, Revised 01/02/2015, Published 01/08/2015

The natural products containing aristolochic acid (AA) have been widely used for acne, gastritis and so on. Recently, it is becoming accepted that AA may be responsible for acute and chronic renal failures as the side effects of Chinese herbs. However, it is unclear what happens in the cells after the AA treatment. In this study, the authors built a gene regulatory network as well as a microRNA–gene regulatory network to investigate the molecular dynamics induced by AA from a systematic perspective. With the regulatory networks, they detected some important pathways and biological processes that were affected by AA treatment, which can help explain the nephrotoxicity and carcinogenicity of AA. They found some important regulators and genes responding to AA treatment, and these genes have been reported to be related to the kidney functions, indicating their important roles in the toxicity of AA.

References

1. 1)
  - 8. He, L., He, X., Lim, L.P., et al: ‘A microRNA component of the p53 tumour suppressor network’, Nature, 2007, 447, (7148), pp. 1130–1134 (doi: 10.1038/nature05939).
2. 2)
  - 32. Rayman, P., Uzzo, R.G., Kolenko, V., et al: ‘Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape’, Cancer J. Sci. Am., 2000, 6, (Suppl 1), pp. S81–S87.
3. 3)
  - 24. Boguslawska, J., Wojcicka, A., Piekielko-Witkowska, A., , Master, A., , Nauman, A.: ‘MiR-224 targets the 3′UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer’, PLoS One, 2011, 6, (9), p. e24541 (doi: 10.1371/journal.pone.0024541).
4. 4)
  - 7. Gui-Min, Q., Xing-Ming, Z.: ‘A survey on computational approaches to identifying disease biomarkers based on molecular networks’, J. Theor. Biol., 2014, 362, pp. 9–16 (doi: 10.1016/j.jtbi.2014.06.007).
5. 5)
  - 42. Theoleyre, S., Mottier, S., Masson, D., , Denis, M.G.: ‘HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas’, Biochem. Biophys. Res. Commun., 2010, 394, (3), pp. 453–458 (doi: 10.1016/j.bbrc.2009.11.163).
6. 6)
  - 9. Chan, J.A., Krichevsky, A.M., Kosik, K.S.: ‘MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells’, Cancer Res., 2005, 65, (14), pp. 6029–6033 (doi: 10.1158/0008-5472.CAN-05-0137).
7. 7)
  - 14. Liu, X., Tang, W.H., Zhao, X.M., , Chen, L.: ‘A network approach to predict pathogenic genes for Fusarium graminearum’, PLoS One, 2010, 5, (10).
8. 8)
  - 17. Liu, K.Q., Liu, Z.P., Hao, J.K., Chen, L., Zhao, X.M.: ‘Identifying dysregulated pathways in cancers from pathway interaction networks’, BMC Bioinf., 2012, 13, p. 126 (doi: 10.1186/1471-2105-13-126).
9. 9)
  - 20. Huang da, W., Sherman, B.T., Lempicki, R.A.: ‘Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists’, Nucleic Acids Res., 2009, 37, (1), pp. 1–13 (doi: 10.1093/nar/gkn923).
10. 10)
  - 32. Rebhan, M., ChalifaCaspi, V., Prilusky, J., Lancet, D.: ‘Genecards: Integrating information about genes, proteins and diseases’, Trends Genet., 1997, 13, (4), p. 163 (doi: 10.1016/S0168-9525(97)01103-7).
11. 11)
  - 16. Anders, S., Huber, W.: ‘Differential expression analysis for sequence count data’, Genome Biol., 2010, 11, (10), p. R106 (doi: 10.1186/gb-2010-11-10-r106).
12. 12)
  - 21. Meng, F., Li, Z., Yan, J., et al: ‘Tissue-specific microRNA responses in rats treated with mutagenic and carcinogenic doses of aristolochic acid’, Mutagenesis, 2014, 29, (5), pp. 357–365 (doi: 10.1093/mutage/geu027).
13. 13)
  - 41. Marques, F.Z., Campain, A.E., Tomaszewski, M., et al: ‘Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs’, Hypertension, 2011, 58, (6), pp. 1093–1098 (doi: 10.1161/HYPERTENSIONAHA.111.180729).
14. 14)
  - 20. Zhang, H.M., Chen, H., Liu, W., et al: ‘Animal TFDB: a comprehensive animal transcription factor database’, Nucleic Acids Res., 2012, 40, (Database issue), pp. D144–D149 (doi: 10.1093/nar/gkr965).
15. 15)
  - 28. Chen, Y.Y., Chung, J.G., Wu, H.C., et al: ‘Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells’, Oncol. Rep., 2010, 24, (1), pp. 141–153.
16. 16)
  - 30. Panzer, U., Steinmetz, O.M., Turner, J.E., et al: ‘Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases’, Am. J. Physiol. Renal Physiol., 2009, 297, (2), pp. F429–F439 (doi: 10.1152/ajprenal.90435.2008).
17. 17)
  - 2. Debelle, F.D., Vanherweghem, J.L., Nortier, J.L.: ‘Aristolochic acid nephropathy: a worldwide problem’, Kidney Int., 2008, 74, (2), pp. 158–169 (doi: 10.1038/ki.2008.129).
18. 18)
  - 5. Chen, Y.Y., Chiang, S.Y., Wu, H.C., et al: ‘Microarray analysis reveals the inhibition of nuclear factor-kappa B signaling by aristolochic acid in normal human kidney (HK-2) cells’, Acta Pharmacol. Sin., 2010, 31, (2), pp. 227–236 (doi: 10.1038/aps.2009.197).
19. 19)
  - 35. Pruitt, K.D., Tatusova, T., Maglott, D.R.: ‘NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins’, Nucleic Acids Res., 2007, 35, (Database issue), pp. D61–D65 (doi: 10.1093/nar/gkl842).
20. 20)
  - 14. Liu, X., Liu, Z.P., Zhao, X.M., Chen, L.: ‘Identifying disease genes and module biomarkers by differential interactions’, J. Am. Med. Inf. Assoc., 2012, 19, (2), pp. 241–248 (doi: 10.1136/amiajnl-2011-000658).
21. 21)
  - 29. Chen, T., Guo, L., Zhang, L., et al: ‘Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats’, BMC Bioinf., 2006, 7, (Suppl 2), p. S20 (doi: 10.1186/1471-2105-7-S2-S20).
22. 22)
  - 19. Betel, D., Koppal, A., Agius, P., , Sander, C., , Leslie, C.: ‘Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites’, Genome Biol., 2010, 11, (8), p. R90 (doi: 10.1186/gb-2010-11-8-r90).
23. 23)
  - 11. Zhao, X.M., Wang, R.S., Chen, L., , Aihara, K.: ‘Automatic modeling of signaling pathways by network flow model’, J. Bioinf. Comput. Biol., 2009, 7, (2), pp. 309–322 (doi: 10.1142/S0219720009004138).
24. 24)
  - 40. Simoes, M.L., Hockley, S.L., Schwerdtle, T., et al: ‘Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53’, Toxicol. Appl. Pharmacol., 2008, 232, (1), pp. 86–98 (doi: 10.1016/j.taap.2008.06.006).
25. 25)
  - 22. Hermeking, H.: ‘The miR-34 family in cancer and apoptosis’, Cell Death Differ., 2010, 17, (2), pp. 193–199 (doi: 10.1038/cdd.2009.56).
26. 26)
  - 33. Alcalay, N.I., Sharma, M., Vassmer, D., et al: ‘Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1’, Am. J. Physiol. Renal Physiol., 2008, 295, (6), pp. F1725–F1734 (doi: 10.1152/ajprenal.90420.2008).
27. 27)
  - 6. Su, Z., Li, Z., Chen, T., et al: ‘Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys’, Chem. Res. Toxicol., 2011, 24, (9), pp. 1486–1493 (doi: 10.1021/tx200103b).
28. 28)
  - 17. Gao, Y., Gopee, N.V., Howard, P.C., , Yu, L.R.: ‘Proteomic analysis of early response lymph node proteins in mice treated with titanium dioxide nanoparticles’, J. Proteomics, 2011, 74, (12), pp. 2745–2759 (doi: 10.1016/j.jprot.2011.08.009).
29. 29)
  - 3. Arlt, V.M., Stiborova, M., Schmeiser, H.H.: ‘Aristolochic acid as a probable human cancer hazard in herbal remedies: a review’, Mutagenesis, 2002, 17, (4), pp. 265–277 (doi: 10.1093/mutage/17.4.265).
30. 30)
  - 4. Cheung, T.P., Xue, C., Leung, K., Chan, K., Li, C.G.: ‘Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products – a consequence of inappropriate nomenclature and imprecise labelling?’, Clin. Toxicol. (Phila), 2006, 44, (4), pp. 371–378 (doi: 10.1080/15563650600671712).
31. 31)
  - 39. Liu, H., Brannon, A.R., Reddy, A.R., et al: ‘Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma’, BMC Syst. Biol., 2010, 4, p. 51 (doi: 10.1186/1752-0509-4-51).
32. 32)
  - 1. Vanhaelen, M., Vanhaelen-Fastre, R., But, P., Vanherweghem, J.L.: ‘Identification of aristolochic acid in Chinese herbs’, Lancet, 1994, 343, (8890), p. 174 (doi: 10.1016/S0140-6736(94)90964-4).
33. 33)
  - 31. Liu, M.C., Lin, T.H., Wu, T.S., , Yu, F.Y., , Lu, C.C., , Liu, B.H.: ‘Aristolochic acid I suppressed iNOS gene expression and NF-kappaB activation in stimulated macrophage cells’, Toxicol. Lett., 2011, 202, (2), pp. 93–99 (doi: 10.1016/j.toxlet.2011.01.021).
34. 34)
  - 37. Xu, J., Song, P., Nakamura, S., et al: ‘Deletion of the chloride transporter slc26a7 causes distal renal tubular acidosis and impairs gastric acid secretion’, J. Biol. Chem., 2009, 284, (43), pp. 29470–29479 (doi: 10.1074/jbc.M109.044396).
35. 35)
  - 23. Faragalla, H., Youssef, Y.M., Scorilas, A., et al: ‘The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma’, J. Mol. Diagn., 2012, 14, (4), pp. 385–392 (doi: 10.1016/j.jmoldx.2012.02.003).
36. 36)
  - 24. Nepusz, T., Yu, H., Paccanaro, A.: ‘Detecting overlapping protein complexes in protein–protein interaction networks’, Nat Methods, 2012, Mar 18:9, (5), pp. 471–472. (doi: 10.1038/nmeth.1938).
37. 37)
  - 36. Wu, X., Weng, L., Li, X., et al: ‘Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis’, PLoS One, 2012, 7, (5), p. e35661 (doi: 10.1371/journal.pone.0035661).
38. 38)
  - 38. Eck, P., Kwon, O., Chen, S., , Mian, L., , Levine, M.: ‘The human sodium-dependent ascorbic acid transporters SLC23A1 and SLC23A2 do not mediate ascorbic acid release in the proximal renal epithelial cell’, Physiol. Rep., 2013, 1, (6), p. e00136 (doi: 10.1002/phy2.136).
39. 39)
  - 25. Yu, H., Jiang, L., Sun, C., et al: ‘Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer’, Gene, 2014, 534, (1), pp. 60–65 (doi: 10.1016/j.gene.2013.10.024).
40. 40)
  - 15. Edgar, R., Domrachev, M., Lash, A.E.: ‘Gene expression omnibus: NCBI gene expression and hybridization array data repository’, Nucleic Acids Res., 2002, 30, (1), pp. 207–210 (doi: 10.1093/nar/30.1.207).
41. 41)
  - 7. Zhao, X.M., Liu, K.Q., Zhu, G., et al: ‘Identifying cancer-related microRNAs based on gene expression data’, Bioinformatics, 2014, 1–9.
42. 42)
  - 26. He, Z., Cen, D., Luo, X., et al: ‘Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor’, Med. Oncol., 2013, 30, (2), p. 557 (doi: 10.1007/s12032-013-0557-0).

Login

Not registered yet?

Share

Tools

Login to add to favourites

Key

Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks

References

Related content